GSK will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline ...

GSK plans to purchase an experimental drug for the liver disease MASH from Boston Pharmaceuticals for $1.2 billion upfront.

GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, a phase III-ready investigational specialty medicine.

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash ...

British pharmaceutical company GSK(GSK) to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for as much as $2 ...

GSK to pay $1.2B upfront to Boston Pharmaceuticals for efimosfermin alfa, a MASH drug candidate. Deal includes $800M in ...

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

GSK GSK1.38%increase; green up pointing triangle will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs. The British ...

GSK will acquire liver-disease treatment efimosfermin from Boston Pharmaceuticals for up to $2 billion to expand its portfolio. The British pharma giant said Wednesday that it will pay the U.S ...